New drug combo shows promise against tough bile duct cancer
NCT ID NCT05451290
First seen Feb 17, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This study tests whether giving a mix of immunotherapy (camrelizumab), a targeted drug (apatinib), and chemotherapy (GEMOX) before and after surgery can help people with advanced bile duct cancer. The goal is to shrink tumors enough for successful removal and to prevent the cancer from coming back. About 30 adults with untreated, locally advanced bile duct cancer are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.